JP2025501141A5 - - Google Patents
Info
- Publication number
- JP2025501141A5 JP2025501141A5 JP2024538669A JP2024538669A JP2025501141A5 JP 2025501141 A5 JP2025501141 A5 JP 2025501141A5 JP 2024538669 A JP2024538669 A JP 2024538669A JP 2024538669 A JP2024538669 A JP 2024538669A JP 2025501141 A5 JP2025501141 A5 JP 2025501141A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- alkylene
- cycloalkyl
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904268 | 2021-12-24 | ||
| AU2021904268A AU2021904268A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051591 WO2023115165A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501141A JP2025501141A (ja) | 2025-01-17 |
| JP2025501141A5 true JP2025501141A5 (enExample) | 2026-01-08 |
Family
ID=86900872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538669A Pending JP2025501141A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163044A1 (enExample) |
| EP (1) | EP4452979A4 (enExample) |
| JP (1) | JP2025501141A (enExample) |
| KR (1) | KR20240128059A (enExample) |
| CN (1) | CN118974044A (enExample) |
| AU (1) | AU2022422215A1 (enExample) |
| CA (1) | CA3241845A1 (enExample) |
| IL (1) | IL313857A (enExample) |
| MX (1) | MX2024007911A (enExample) |
| WO (1) | WO2023115165A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| TW202425965A (zh) | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| EP4735441A1 (en) | 2023-06-28 | 2026-05-06 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| JP2026524104A (ja) * | 2023-06-28 | 2026-07-17 | サイロ プロプリエタリー リミテッド | 化合物 |
| WO2026030052A1 (en) | 2024-07-31 | 2026-02-05 | Fmc Corporation | Fungicidal substituted azoles |
| WO2026137050A1 (en) * | 2024-12-24 | 2026-07-02 | Psylo Pty Ltd | Compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5977131A (en) * | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| GB9819020D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| EP1513521A2 (en) * | 2002-05-30 | 2005-03-16 | Alcon, Inc. | Pyranoindazoles and their use for the treatment of glaucoma |
| US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| ES2374581T3 (es) | 2006-07-06 | 2012-02-20 | Abbott Healthcare Products B.V. | Derivados de azaindol con una combinación de agonismo parcial del receptor nicotínico de la acetilcolina e inhibición de la reabsorción de dopamina. |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| PL2485731T4 (pl) * | 2009-10-06 | 2017-07-31 | Millennium Pharmaceuticals, Inc. | Związki heterocykliczne użyteczne jako inhibitory PDK1 |
| US9073851B2 (en) * | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
| WO2017125351A1 (en) | 2016-01-21 | 2017-07-27 | Laboratorios Lesvi Sl | Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole |
| CA3182093A1 (en) * | 2020-06-10 | 2021-12-16 | Florence Wagner | Tricyclic psychoplastogens and uses thereof |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
-
2022
- 2022-12-23 JP JP2024538669A patent/JP2025501141A/ja active Pending
- 2022-12-23 KR KR1020247024904A patent/KR20240128059A/ko active Pending
- 2022-12-23 CA CA3241845A patent/CA3241845A1/en active Pending
- 2022-12-23 CN CN202280091203.9A patent/CN118974044A/zh active Pending
- 2022-12-23 AU AU2022422215A patent/AU2022422215A1/en active Pending
- 2022-12-23 MX MX2024007911A patent/MX2024007911A/es unknown
- 2022-12-23 WO PCT/AU2022/051591 patent/WO2023115165A1/en not_active Ceased
- 2022-12-23 EP EP22908927.1A patent/EP4452979A4/en active Pending
- 2022-12-23 IL IL313857A patent/IL313857A/en unknown
- 2022-12-23 US US18/722,007 patent/US20250163044A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501630A5 (enExample) | ||
| JP2025501629A5 (enExample) | ||
| JP7664201B2 (ja) | アミロイド標的剤及びその使用方法 | |
| US11459327B1 (en) | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | |
| CN108366996B (zh) | 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 | |
| JP6292736B2 (ja) | ピロールスルホンアミド誘導体、その製造法およびその医療用途 | |
| TWI798470B (zh) | 作為神經激肽－１受體拮抗劑的化合物及其用途 | |
| WO2020047208A1 (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
| JP2012520324A5 (enExample) | ||
| JP2017502080A (ja) | マラリアの治療のための化合物及び方法 | |
| CN110156656B (zh) | 五元杂芳环衍生物、其制备方法、药物组合物及应用 | |
| JP2024534572A5 (enExample) | ||
| UA100192C2 (en) | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
| JP2010500334A5 (enExample) | ||
| JP2025081626A (ja) | ペンタミジンの類似体及びその使用 | |
| WO2019224667A1 (en) | Indanes as nrf2 activators | |
| TWI641584B (zh) | α－取代甘胺醯胺衍生物 | |
| EA027882B1 (ru) | Этинильные производные в качестве антагонистов метаботропного глутаматного рецептора | |
| KR20000068436A (ko) | 디아민 유도체 및 이를 함유하는 의약 | |
| JP6712331B2 (ja) | Ｊａｋ阻害剤としてのピラゾリルアミノベンズイミダゾール誘導体 | |
| JP2025507543A5 (enExample) | ||
| JPWO2019059344A1 (ja) | 化学活性化型水溶性プロドラッグ | |
| WO2021077102A1 (en) | Novel antiparasitic compounds and methods | |
| KR20240144338A (ko) | 비타민 d 유도체의 결정 또는 그 용매화물의 결정 | |
| TW202322794A (zh) | 做為鈉通道活化劑之吡啶基衍生物 |